News
Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, ...
The Window of Opportunity: Why Early Biologic Use Matters for Patients With Hidradenitis Suppurativa
Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and ...
2d
Medpage Today on MSNGLP-1 Drugs May Hold Benefit in Painful Skin Disease
In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...
Hidradenitis suppurativa patients face higher depression and anxiety risks, but biologic treatments may reduce these mental ...
7h
TipRanks on MSNIncyte’s Promising Phase 3 Study on Ruxolitinib Cream for Hidradenitis Suppurativa
Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Study Overview: Incyte Corporation is conducting a Phase ...
GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...
Explore how hidradenitis suppurativa is linked to increased rates of depression and anxiety, with no clear connection to ...
UCB, a global biopharmaceutical company, hosted its 2025 Hidradenitis Suppurativa (HS) Summit, which aimed to create a ...
Hidradenitis suppurativa is associated with a higher risk for new-onset depression and anxiety, which may occur despite treatment, according to a Danish population-based cohort study.
Avalo Therapeutics (NASDAQ:AVTX) stock rises as Cantor Fitzgerald launches coverage with an Overweight rating, highlighting its lead asset, AVTX-009. Read more here.
ZUG, Switzerland, August 5, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results